Another study showed that KEAP1/NFE2L2 mutations predict lung cancer radiation resistance, which can be targeted by glutaminase inhibition: glutaminase inhibitors preferentially radio-sensitize KEAP1/NFE2L2-mutant tumor cells via the depletion of glutathione and increased radiation-induced DNA damage [91]. This evidence concerns the gene GLS and lung carcinoma.